Aug 28 (Reuters) – Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission’s website showed.
• Kimberly-Clark announced the takeover in November last year.
• The deal was expected to close in the second half of 2026, it said at the time.
• Kimberly-Clark forecast $2.1 billion in annual cost savings from the deal.
• The addition of Kenvue’s vast portfolio of brands from Listerine mouth wash to skincare names like Aveeno and Neutrogena is expected to bring in annual revenues of roughly $32 billion for the combined company, it said.
(Reporting by Bart Meijer;Editing by Sudip Kar-Gupta)
Source link
Author
- Ytv Market News
- Share-market news writer and analyst with deep experience covering equities, commodities, forex, and cryptocurrencies for readers in the USA, UK, Canada, and Australia. Ytv Market News delivers timely market updates, practical trading insights, and clear explanations of macro and company-level catalysts that move prices. Combines on-the-ground financial reporting with technical analysis, using concise charts and actionable ideas to help investors and traders make smarter decisions.
Latest entries
GermanyAugust 29, 2026Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
CanadaAugust 29, 2026Laurentian Bank of Canada declares dividend on its common shares and announces the termination of its Shareholder Dividend Reinvestment and Share Purchase Plan- Crypto NewsAugust 29, 2026Why Bitcoin Crashed After Warsh’s Jackson Hole Speech – and What Happens Next
Crypto NewsAugust 29, 2026Tokenized gold is becoming productive collateral in crypto lending, Arch says
